INTRODUCTION
Early descriptions of mitotic and spindle aberrations in human tumors date from approximately a century ago; however, for many decades, the progress in cancer cytogenetics was hampered by technical challenges in assessing the nuclear chromosomal content. In the late 1950s and the 1960s, significant methodological achievements regarding culture and mitotic arresting of cells made the detection of chromosomal abnormalities possible, although without an accurate identification of the occurring changes. The typical example is the description in patients with chronic myeloid leukemia, of the Philadelphia (Ph) chromosome, which initially was depicted as a deleted chromosome 21 or 22 [1] . The flourish of chromosomal banding techniques (Q-, G-, R-banding) in the early 1970s has contributed to the establishment of karyotype-phenotype correlations for a rapidly increasing number of diseases. Characteristic recurrent translocations were rapidly identified in hematopoietic and soft tissue neoplasias and have helped in the identification of chromosomal loci containing genes involved in the genesis of these tumors [2] . Conversely, the impact of cytogenetic technology on understanding molecular mechanisms involved in the initiation and progression of solid tumors has been less valuable. Solid tumors are commonly associated with an array of orchestrated genetic changes, and the identification of changes causally related to the carcinogenic process has been frustratingly slow, mainly as a consequence of the enormous volume of secondary abnormalities reflecting the phenomenon of genomic instability.
FLUORESCENCE IN SITU HYBRIDIZATION (FISH) AND INTERPHASE ANALYSIS
Classical cytogenetics represented by chromosomal banding techniques was successful in correlating karyotype abnormalities with diagnosis, prognosis, and response to therapy in hematological neoplasias. However, these techniques require a high rate of cell division and good chromosomal morphology, which represent challenges for the cytogeneticists, and a long period for assaying and analyzing, which usually is a challenge for physicians (Table 1) . Thus, it was not surprising that an outburst of progress in the cancer cytogenetics field followed the advent of molecular cytogenetics, with the development and optimization of FISH technology [3] . FISH technology initially focused on research issues, but soon was applied to clinical questions and has proved sufficiently sensitive and reliable to fill in the gap between classic karyotyping and highly sensitive molecular techniques. 46 The basis for the molecular cytogenetics technology is the complementary double-stranded nature of DNA. A specific DNA segment is converted into a probe through the attachment of a fluorescent tag or a reporter molecule that later in the procedure will be conjugated with a fluorescent tag. The probe is denatured, exposed to a similarly denatured target DNA, and, under proper hybridization conditions, recognizes and binds to the homologous sequences in the target DNA. After hybridization, the copy number and location of the fluorescent tags, and consequently, of the target homologous regions, are recognized under fluorescence microscopy both in chromosome spreads and in interphase nuclei (Fig. 1) . FISH technology is simple and robust, and its phenomenal contribution to the cancer field largely relies on its applicability to interphase cells (Table 1) .
Molecular Cytogenetics in Clinical Oncology
While early FISH applications aimed at the detection of numerical abnormalities in mitotic or interphase cells, as well as structural abnormalities in metaphase spreads, a milestone was achieved in 1990 when Rowley et al. [4] and Tkachuck et al. [5] developed strategies for identification of chromosomal translocations in interphase cells. Since then, variations in probe design, and consequently, in the presentation of fluorescent signals in normal cells and in cells carrying chromosomal translocations have been developed for molecularly cloned rearrangements. In the standard approach for interphase evaluation of chromosomal translocations [5] , a DNA probe, comprising sequences mapped proximally to the breakpoint in one of the chromosomes involved in the reciprocal translocation, is combined with a differentially labeled DNA probe that includes sequences mapped distally to the breakpoint in the other chromosome. Positive nuclei for the translocation display one dual-color fusion signal, representing one of the derivative chromosomes generated by the translocation, and two single-color signals, one for each of the normal alleles ( Fig. 2A) . This standard FISH strategy has largely been used for the diagnosis of leukemia and lymphoma translocations at disease presentation or at clinical relapse, since patients at these stages usually show high frequencies of bone marrow cells with the chimeric gene. Nonetheless, for detection of residual disease, this approach lacks specificity, because cells with random spatial colocalization of normal signals with different colors, usually found in frequencies ranging from 1%-5% of scored nuclei, are seen as false positives.
To minimize this problem, a dual-fusion FISH (D-FISH) approach was developed, with the probe set including DNA sequences that encompass proximally and distally the translocation breakpoints on both chromosomes involved in the translocation.
As illustrated for the t(8;21)(q22;q22) in Figure 2B , sequences for each chromosome are labeled with a specific color, and the translocation generates fused signals in both derivative chromosomes [6] . Using the D-FISH approach, nuclei carrying the reciprocal translocation show two copies of the fused signals and one copy of each of the single signals representing the normal alleles. It is doubtful that such a positive pattern would be mimicked by artificial conditions; therefore, the D-FISH approach shows a higher sensitivity that favors its application in patients in clinical remission who are expected to present low frequencies of abnormal cells [7] . [8, 9] ; the molecular events triggered by these rearrangements have yet to be characterized. Conversely, solid tumors usually present large numbers of derivative chromosomes from translocations involving two or more chromosomes [10] , suggesting that some critical cancer genes are promiscuous in the selection of translocation partners. Promiscuity in translocation partnership is well known for leukemia genes such as mixed-lineage leukemia and E2A [11] , and a third FISH strategy was developed to address this particular condition, namely, "break-apart" FISH. The break-apart probe comprises DNA sequences mapped proximally and distally to the breakpoint within a critical gene labeled with distinct fluorochromes [12] . In this case, the fused fluorescent signals represent a normal gene, whereas nuclei with disruptions within the target gene due to translocations show one fusion signal for the normal allele and two 48 [6] . C) Break-apart format for cancer genes with promiscuous partners is illustrated for the gene E2A [12] .
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Varella-Garcia 49 single-color signals, one for each of the derivative chromosomes, regardless of which chromosome is the partner in the translocation (Fig. 2C ).
FISH VARIANTS: COMPARATIVE GENOMIC HYBRIDIZATION AND MULTICOLOR KARYOTYPING
Two major variants of FISH technology, comparative genomic hybridization (CGH) and multicolor karyotyping, have been extensively applied to solid tumors; their advantages and shortcomings are summarized in Table 1 . CGH was developed by Kallioniemi et al. [13] and allows the visualization of gains and losses in the copy numbers of DNA sequences from specific chromosomal regions without involving cell culture, as illustrated in Figure 3A . The genomic DNA from the tumor specimen is isolated, fragmented, and labeled with a given fluorophore, for instance, the green fluorophore fluorescein isothiocyanate (FITC). A sample of normal genomic DNA, taken as a reference, is similarly isolated and fragmented but is differentially labeled, for instance, with the red fluorophore Texas Red. Subsequently, equal amounts of tumor and reference DNA are coprecipitated with an excess of repeat-rich DNA (Cot-1 DNA) for the blocking of the repetitive sequences, and this DNA mixture is allowed to hybridize to normal metaphase spreads. Sequences of DNA from each specific chromosomal region recognize their homologous regions in the normal template metaphases and hybridize to them according to the proportion in which they are represented in the DNA mixture. Comparative analysis of the proportion of each distinctly labeled tumor and reference DNA that was incorporated into the template metaphase provides a ratio of tumor to normal signal against a baseline of the metaphase chromosomes. Therefore, the normal number of chromosome regions with copies in both the tumor and reference DNA of a chromosomal region will display a balanced profile of Texas Red and FITC fluorophores, whereas regions deleted in the tumor will show a higher profile of Texas Red, and regions with gains in copy number in the tumors will show a higher profile of FITC. Figure 3B illustrates the typical pattern for presentation of results generated by CGH analysis. In the prostate carcinoma illustrated in Figure 3B , for instance, gene amplifications were found for the oncogene MYC (at 8q24) and the vitamin D receptor gene (at 12q12-q14), which mediates growth inhibitory effects of vitamin D in prostate cancer. The CGH technique has been extensively used for solid tumor analysis since its inception, and a nonrandom pattern of genomic imbalances has emerged from these studies [14] . To this point, CGH has been the most helpful cytogenetics tool for identification of oncogenes and tumor suppressor genes involved in the initiation and progression of solid tumors, guiding the more detailed genetic analysis to specific chromosomal regions.
Two major multicolor karyotyping techniques are spectral karyotyping (SKY) and multiplex-FISH (M-FISH). These techniques are similarly based on combinatorial probe-labeling schemes with five spectrally discrete fluorochromes that uniquely paint all 24 human chromosomes (Fig. 4) but differ in their analytical procedures. SKY relies on a single digital image acquired with a charge-coupled device (CCD) in conjunction with a customized multiband optical filter, and on Fourier spectroscopy [15] . An interferometer is used to access the spectrum of fluorescence wavelengths for each pixel of the image. A dedicated computer program identifies the components of the spectrum, applying a classification algorithm, and generates a composite image in which each chromosome is pseudocolored based on its fluorochrome signature. Since each chromosome is represented by one specific color, rearrangements involving different chromosomes are easily recognized (Fig. 5) . On the other hand, the M-FISH technique combines monochrome CCD images acquired separately for each of the five spectrally distinguishable fluorochromes ( Fig.  6 ) and has them subsequently analyzed by a dedicated software program that also builds a composite image by assigning a particular pseudocolor to each chromosome [16] . Thus, both multicolor karyotyping techniques are specially tailored to identify and characterize the complex chromosomal rearrangements found in solid tumor cells. Nevertheless, these methodological approaches are unable to detect intrachromosome rearrangements, such as inversions and deletions, since these specific abnormalities maintain the correct color for abnormal chromosomes. Consequently, multicolor karyotyping cannot replace standard banding karyotyping; rather, both techniques should be used in conjunction for a comprehensive evaluation of solid tumors.
Application of multicolor karyotyping technology to solid tumors faces most of the constraints of classic cytogenetics regarding the need for dividing cells and long chromosomes with good morphology in well-spread metaphases. These features are very difficult to achieve simultaneously in primary tumors, and both the SKY and M-FISH techniques have been more commonly applied to cell lines established from primary tumors. The immortal lines offer more suitable material for karyotype analyses, and identification of chromosomal regions/genes involved in rearrangements provides interesting clues in the mechanisms of tumorigenesis [17] .
CURRENT PROGRESS ON SOLID TUMORS: SLOWLY BUT SURELY
The interphase FISH technology opened a new window of research opportunities in solid tumors, largely due to the availability of formalin-fixed, paraffin-embedded tumor blocks that could be used both for prospective and retrospective studies. The ability to keep the tissue architecture 50 Molecular Cytogenetics in Clinical Oncology and, consequently, to reveal cell-to-cell heterogeneity and detect small clones of genetically distinct cells is very appealing and may be essential in achieving breakthroughs in current cancer therapy, as stressed by Kobayashi et al. [18] . Those authors established four sublines from a primary pulmonary adenocarcinoma characterized by a poor prognosis. These sublines differed in morphological, biochemical, and genetic findings, and one of them exhibited a 12-fold amplification of the c-MYC oncogene and an increased sensitivity to cytosine arabinoside. However, a serious caveat for the broader application of FISH technology as a diagnostic tool for solid tumors is the scarceness of specific abnormalities associated with them. Recent progress in the DNAlabeling strategies using new fluorophores has partially circumvented this lack of specific targets, allowing the design of multicolor FISH probes that simultaneously target at least four different chromosomal regions in a single cell. The multicolor strategy is particularly useful for analysis of solid malignancies characterized by polyploidy or polysomy for multiple chromosomes, as addressed later in this review. In addition, among the latest publications, there is an emerging variability in applications of FISH as an adjunct diagnostic tool, which attests to the encouraging progress recently achieved. Examples are described below and summarized in Table 2 . 
Diagnosis and Follow-Up
An interesting illustration is the differential diagnosis between teratoid/rhabdoid (AT/RT) and medulloblastomas/central primitive neuroectodermal (MB/PNET) tumors through the deletion of chromosome 22q11.2 sequences. AT/RT is a rare intracranial neoplasm typically unresponsive to therapy and rapidly fatal, and approximately 90% of patients present with a 22q deletion [19] . Bruch et al. [20] have shown the diagnostic use of a 22q11.2 FISH probe in specimens with equivocal primitive central nervous system neoplasms. "Difficult to classify" tumors were assigned to AT/RT (when 22q deletion was present) or MB/PNET groups (when 22q deletion was not present), and after diagnosis reclassification, the study concluded that misdiagnosed cases of AT/RT had probably accounted for the worse prognosis associated with MB/PNET in younger infants.
An attempt has been made to use FISH to monitor surgical margins. The combination of multiple DNA probes successfully identified chromosome imbalances associated with malignancy in head and neck squamous cell carcinomas that were also present in clinically normal adjacent cells, thereby detecting subclinical tumorigenesis [21] . In some patients, aneusomy in surgical margins was found in specimens for which the pathological evaluation was negative; these patients relapsed and died within the 3-year follow-up [22] . Although a question remained regarding the practicability of FISH as an intraoperative tool because, currently, results cannot be provided within an intraoperative time frame, the FISH results from these head and neck carcinomas strongly reinforced the need for adjunct therapy for patients with molecularly abnormal margins.
Additional examples are emerging regarding the applicability of FISH assays to accurately monitor tumor response to therapy and to offer the clinician extra arguments for changing ineffective therapy at an earlier stage in the course of treatment. The cytologic examination of cerebrospinal fluid (CSF) is the primary method for evaluation of response to therapy for metastatic spread to the leptomeninges; a diffuse and often multifocal infiltration of the leptomeninges is estimated to occur in up to 8% of patients 52 with systemic cancer [23] . However, this cytodiagnosis loses much of its sensitivity through the course of protracted therapy because CSF undergoes a decrease in cellularity, changes in cell morphology, and presentation of reactive ependymal cells. Van Oostenbrugge et al. [24] tested leptomeningeal metastases from three cases of non-Hodgkin's lymphoma, three cases of breast cancer, and one malignancy with unknown primary site using a single FISH probe (chromosome 1 centromere), and found a better correlation between FISH and treatment response than routine cytodiagnosis. This study was performed retrospectively; however, the authors conceded that had the FISH results been taken into account, the treatment would have changed for four of the seven patients with normal or suspicious cytology in the ventricular CSF but aneusomic cells detected by FISH. Interestingly, in that study, the chromosome 1 probe was selected as a nonspecific indicator of chromosome aneusomy rather than a specific marker for the patients' diseases.
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Markers for Prognosis and Targets to Therapy
Examples of biomarkers that reliably predict responses to chemotherapy for solid tumors are rare but nonetheless rapidly increasing, and FISH technology has expanded the availability of molecular targets to be evaluated. The dualcolor FISH assay for evaluation of HER-2 (erbB2) gene amplification in breast cancer is probably the utmost investigated FISH test that has proven to be effective as a prognostic marker and predictor for response to therapy in solid malignancies. Overexpression of HER-2 has been found in 20%-30% of breast cancers and has been associated with a poor overall survival [25, 26] and response to therapy [27, 28] . Trastuzumab, a humanized monoclonal antibody that recognizes the HER-2 protein, produced objective responses, alone or in combination with chemotherapy, in breast cancer patients previously untreated and in the secondline setting [29] [30] [31] [32] . Although it might be predicted that protein expression would be more effective for assessing response to trastuzumab therapy, because the antibody binds to the cell surface protein, results from a FISH assay using HER-2 and chromosome 17 centromere sequences showed that the presence of gene amplification (Fig. 7) correlated better with survival, was more accurate and reliable for selecting patients eligible for treatment with trastuzumab, and was superior for predicting response to therapy [33] [34] [35] [36] .
The success of targeting HER-2 for therapy in breast cancer has yet to be validated in other epithelial tumors. In lung and prostate carcinomas, it is clear that only a minority of patients overexpress HER-2 due to gene amplification [37, 38] . Intriguingly, the expression patterns of HER-2 are different in breast and lung carcinomas (Fig. 8) , and most lung tumors display gains in copy number of HER-2 gene per cell due to chromosomal aneusomy rather than gene amplification. Initial reports show that prostate adenocarcinoma patients without HER-2 amplification have not responded to trastuzumab [39] , while experiments in lung cancer cell lines indicate that trastuzumab was effective in reducing cell growth when multiple copies of the gene were present, even as a consequence of aneusomy [40] . Therefore, studies to determine the effectiveness of trastuzumab in relation to the molecular profiling of patients regarding HER-2 status are urged.
Another member of the HER family of receptors, the epidermal growth factor receptor (EGFR), has been postulated as a potential marker for prognosis and a target for therapy in solid malignancies. Recent studies have shown promising results with tyrosine kinase inhibitors of EGFR (ZD1839 and OSI-774) in patients with esophageal [41] and lung carcinomas. In non-small-cell lung carcinomas, ZD1839 (Iressa ® ; AstraZeneca; London, UK) produced objective responses in about 15%-20% of patients with advanced disease who had failed one or two chemotherapy regimens (at least one platinum based) and in 10% of patients who had failed two or more prior chemotherapy regimens containing platinum and docetaxel, with a favorable adverse event profile [42, 43] . These findings raised considerable excitement regarding the potential role of Varella-Garcia such therapies for lung cancer patients with less advanced disease and their potential to improve survival. Nevertheless, there is little information on how patients who might benefit from therapy with EGFR inhibitors should be selected. An interesting finding from the University of Colorado (Hirsch et al. submitted for publication) was the positive correlation between the level EGFR protein expression and copy number of the gene per cell, suggesting that an additive effect of gene copies is an important mechanism for EGFR protein expression in lung cancer cells.
Other key regulator genes for cell growth, proliferation, and differentiation processes, such as the MYC (8q24), MYCN (2p24.1), and CCND1 (cyclin D1, 11q13), have been less evaluated clinically in solid tumors. However, when these genes are erroneously expressed due to genetic rearrangements, such as translocation or gene amplification, neoplastic transformation is activated, and their molecular pathways are potential therapy targets. FISH probes are commercially available for these genes, and in the future, may be utilized similarly to the HER-2 probe.
Diagnosis of Recurrent Disease
Detection of residual disease in patients with solid malignancies is an essential goal in clinical oncology, and FISH technology has already been introduced as a tool in this area. One of the promising applications of interphase FISH is the detection of tumor cells in body fluids through noninvasive procedures, as illustrated by the detection of tumor cells in urine of patients with urothelial carcinomas. Urinary cytology has been the reference test for the evaluation of symptomatic patients, for the detection of lesions in high-risk patients, and for the follow-up of patients with a prior history of transitional cell carcinoma (TCC).
Although routine cytology has a relatively high level of specificity for the detection of high-grade in situ and invasive lesions, the sensitivity for patients with low-grade TCC is low, because these tumors may exfoliate cells that are cytologically indistinguishable from normal. Urine cytology is further limited by poor specificity for clinically significant lesions in cases that are classified as atypical on the basis of cells with equivocal cytologic features. The cytologic diagnosis of atypia may result from degenerative changes related to prior therapy or reactive changes that are of limited clinical significance. Therefore, the clinical outcomes for individual cases cannot be accurately determined by cytologic examination alone. As a result, many patients undergo unnecessary procedures to rule out malignancy based on limited specificity for clinically significant lesions. The U.S. Food and Drug Administration (FDA) recently approved the UroVysion ™ Bladder Recurrence Cancer Test (Vysis; Downers Grove, IL) for the detection of TCC in urine cells. The UroVysion ™ test was designed for interphase cell quantification of chromosomes 3, 7, 17, and 9p21 region (p16/CDKN2A gene), which were recognized as frequently involved in numerical anomalies in bladder cancer [44] . In a series of 265 patients, Halling et al. [45] demonstrated a significantly greater overall sensitivity of FISH over cytology for the detection of pTis, pT1-pT4, and grade 3 urothelial carcinoma. Validation of the UroVysion ™ FISH assay as a screening tool for selection of patients with a history of bladder cancer who should be submitted to cystoscopy has been performed in numerous institutions, including the University of Colorado. Although false-negative FISH results can be expected in low-grade TCC due to frequent diploid chromosomal content, in our small series of 19 patients, urine specimens from two patients with G1 tumors and one patient with a G2 tumor were classified as negative by cytology but abnormal by FISH. Figure 9 illustrates an abnormal cell found in the G2 TCC patient confirmed by cystoscopy in our series, showing multiple copies of each of the four DNA targets included in the UroVysion ™ probe set. Interestingly, the UroVysion ™ test also was proven to be effective in detecting tumor recurrence before evidence of urothelial carcinoma was found on biopsy, likely due to the ability of voided urine to present the entire urothelium versus the regional evaluation of the biopsy [45] . A follow-up biopsy revealed recurrent urothelial carcinoma in 7 out of 11 patients identified by Halling at al. [45] as abnormal by FISH but with a negative initial biopsy. Therefore, patients with positive FISH but negative biopsy should be carefully followed, as they are at risk of harboring occult disease.
Other recently developed multicolor FISH probes were demonstrated to be potentially useful laboratory tools in the effort to reduce mortality from solid tumors, due to their greater ability to diagnosis early changes, and therefore, prevent disease progression. Examples include the analysis of cells collected through minimally invasive approaches, such as epithelial cells obtained in fine needle aspirates from ductal carcinoma of the breast [46] and in bronchial biopsies from smokers at risk for lung carcinoma [47] . The multicolor probe used in the bronchial biopsies study, LAVysion ™ (Vysis), addresses four chromosomal regions or genes commonly involved in gains in lung carcinomas: 5p15, 6 centromere, 7p12 (EGFR), and 8q24 (MYC), as illustrated in Figure 10 . Normal bronchial cells are shown with two copies of each of these DNA targets, and a nucleus from a squamous cell carcinoma is shown with multiple copies of each target.
The development of innovative technologies for unbiased recovery and enrichment of tumor cells from by on April 17, 2008 www.TheOncologist.com peripheral blood or bone marrow aspirates using magneticactivated cell-sorting systems [48] , coupled with accurate tests to characterize these cells, is expected to better monitor the response to cytotoxic or hormonal therapy and to identify patients at risk for relapse. FISH has been proposed as an essential test to be combined with immunophenotyping for evaluation of potential tumor cells selected from blood or bone marrow. Engel et al. [49] , in dilution assays with the breast cancer cell line MCF7 and normal peripheral lymphocytes, demonstrated the higher sensitivity of FISH tests using centromeric probes compared with flow cytometry sorting using anticytokeratin and anti-CD45 antibodies. In addition, these authors successfully identified circulating tumor cells in the peripheral blood of 30 out of 43 patients with breast or ovarian cancer using one locusspecific (17q11-12) and three centromeric probes (chromosomes 7, 12, and 17) in combination with anticytokeratin and anti-CD45 antibodies.
Risk Assessment
There are persisting concerns regarding the carcinogenic risk to therapeutically irradiated patients, because it is well known that ionizing radiation is a major aneugenic and clastogenic agent [50] . The application of emerging molecular cytogenetic methods to risk assessment may help to clarify the uncertainties of low-risk exposure to cancer treatments, such as radioactive iodine for thyroid disease. Ramirez et al. [51] tested a new FISH probe set, that included the centromere of chromosome 17 and the p53 locus (17p13.1), in buccal cells from patients with thyroid cancer before and after radioactive iodine treatment. The rationale for the selection of these probes was that the failure to express a functional nuclear phosphoprotein p53 plays a critical role in the cellular response to DNA damage, leads to aneuploidy in vitro and in vivo, and increases the incidence of spontaneous tumors [52, 53] . Inactivation of p53 is frequently associated with the loss or mutation of its encoding gene, TP53. In that study, the radiationinduced chromosome breakage resulted in a significant increase in 17p gains and losses in exposed individuals. Therefore, the 17cen/p53 FISH assay may be a potential biomarker for cancer risk in people therapeutically exposed to radiation.
CONCLUSIONS
The identification of specific chromosomal abnormalities in leukemias, lymphomas, and soft tissue tumors has provided critical insight into the molecular changes that underlie carcinogenesis. In solid malignancies, the progress was less substantial until the development of molecular cytogenetic techniques such as interphase FISH, CGH, and multicolor karyotyping. SKY and M-FISH, the two major multicolor karyotyping techniques, contribute to the identification of complex chromosomal changes associated with solid tumors, and CGH has highlighted critical regions harboring oncogenes and tumor suppressor genes. Interphase FISH technology has been demonstrated to be specially suitable to bridge basic research to clinical practice, and its applicability has increased substantially in a short time. These new methodological strategies are rapidly expanding the application of cytogenetic assays to critical areas in solid malignancies at both the basic science and clinically applied levels.
Availability of reliable and specific markers for individual diseases or stages is a critical shortcoming in the current application of FISH to solid tumors, and the development of a substantial number of DNA probes is warranted for a more powerful use of the technology. In this regard, the massive volume of molecular information that has been constantly released in both the fields of genome databases and tumor profiling is expected to minimize the current difficulties. Additionally, automated devices are currently under development to process and analyze interphase FISH assays, which are expected to reduce the burden of the labor-intensive aspect of the molecular cytogenetics procedures. As a consequence, molecular cytogenetic technology is shortly expected to extend its contribution to more accurate tumor profiling; improved early detection, diagnosis, and prognosis; selection of target therapeutic approaches, and monitoring clinical outcome in patients with solid malignancies.
